title: Effects of hydrogen sulfide synthesis inhibitors on posthypoxic ventilatory behavior in the C57BL/6J mouse.
abstract: BACKGROUND
  H(2)S synthesis inhibitors (HSSI) have been shown to impact respiratory control. For instance, the HSSI hydroxylamine (HA) decreases the respiratory discharge rate from isolated medullary sections, and HA in addition to other HSSIs propargylglycine and amino-oxyacetic acid (AOAA) have been found to reduce hypoxic responsiveness.
  
  
  OBJECTIVE
  The aim of this study was to determine if administration of HSSIs could improve respiratory stability in an intact organism prone to recurrent central apneas.
  
  
  METHODS
  Saline and HSSI compounds were administered to C57BL/6J mice (n = 24), a strain predisposed to recurrent central apneas, prior to measurement of hypoxic and posthypoxic ventilatory behavior.
  
  
  RESULTS
  Administration of HA and AOAA resulted in a significantly smaller percentage of animals expressing one or more apneas during reoxygenation compared to saline control, and animals given AOAA demonstrated a smaller coefficient of variation for frequency during reoxygenation, a marker suggesting greater respiratory stability. This occurred despite varying effects of the three HSSI compounds on hypoxic ventilatory response.
  
  
  CONCLUSIONS
  Instability and pause expression are improved by targeting H(2)S synthesis, an effect not predicted by effects on hypoxic responsiveness.
authors.affiliation: Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
authors.forename: Lucas M
authors.initials: LM
authors.lastname: Donovan
authors.forename: Michael W
authors.initials: MW
authors.lastname: Moore
authors.forename: Carl B
authors.initials: CB
authors.lastname: Gillombardo
authors.forename: Sam
authors.initials: S
authors.lastname: Chai
authors.forename: Kingman P
authors.initials: KP
authors.lastname: Strohl
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006146:Guanidines / Q000494:pharmacology; D006862:Hydrogen Sulfide / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019811:Hydroxylamine / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D012123:Pulmonary Ventilation / Q000187:drug effects*; D011730:Pyridoxal / Q000494:pharmacology; D012120:Respiration Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D015656:Respiratory Mechanics / Q000187:drug effects*; D020182:Sleep Apnea, Central / Q000188:drug therapy* / Q000503:physiopathology; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C112418:32-ascomycinyloxyacetic acid; D006146:Guanidines; C549858:pyridoxylidene aminoguanidine; D019811:Hydroxylamine; D011730:Pyridoxal; D016559:Tacrolimus; D006862:Hydrogen Sulfide